Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome ; volume:43 ; number:02 ; year:2010 ; pages:e1-e1
Hormone and metabolic research ; 43, Heft 02 (2010), e1-e1
- Contributor
-
Bogazzi, F.
Lombardi, M.
Russo, D.
Sardella, C.
Raggi, F.
Brogioni, S.
Cetani, F.
Ceccarelli, C.
Mariani, G.
Basolo, F.
Martino, E.
- DOI
-
10.1055/s-0030-1268482
- URN
-
urn:nbn:de:101:1-2018102212203925922677
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bogazzi, F.
- Lombardi, M.
- Russo, D.
- Sardella, C.
- Raggi, F.
- Brogioni, S.
- Cetani, F.
- Ceccarelli, C.
- Mariani, G.
- Basolo, F.
- Martino, E.
Other Objects (12)
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Piepke goh glatt aff, glatt aff,
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Piepke goh glatt aff, glatt aff,
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients